Liraglutide Safety, Tolerability, and Pharmacokinetics Investigated in Obese Adolescents (12-17 Years)
A Randomised, Double-blind, Placebo-controlled Trial to Assess Safety, Tolerability and Pharmacokinetics of Liraglutide in Obese Adolescent Subjects Aged 12 to 17 Years
Abstract
A randomized, double-blind, placebo-controlled Phase 1 trial assessed liraglutide's safety, tolerability, and pharmacokinetics in obese adolescents aged 12-17 years.